Preferred Label : uracil;

MeSH definition : One of four nucleotide bases in the nucleic acid RNA.;

MeSH CAS label : 2,4(1H,3H)-Pyrimidinedione;

MeSH Related Number : 66-22-8 (Uracil);

Registry Number MeSH : 66-22-8;

MeSH annotation : /biosyn /physiol permitted; uracil deoxyriboside, uracil deoxyribonucleoside DEOXYURIDINE; uracil riboside, uracil ribonucleoside URIDINE; uracil deoxyriboside, uracil deoxyribonucleoside DEOXYURIDINE; uracil riboside, uracil ribonucleoside URIDINE;

Wikipedia link : https://en.wikipedia.org/wiki/Uracil;

Codes EINECS : 200-621-9;

Is substance : O;

UNII : 56HH86ZVCT;

InChIKey : ISAKRJDGNUQOIC-UHFFFAOYSA-N;

Details


Main resources

You can consult :

One of four nucleotide bases in the nucleic acid RNA.

https://www.has-sante.fr/portail/jcms/c_2891090/fr/methodes-de-recherche-d-un-deficit-en-dihydropyrimidine-deshydrogenase-visant-a-prevenir-certaines-toxicites-severes-associees-aux-traitements-incluant-une-fluoropyrimidine-5-fluorouracile-ou-capecitabine
https://www.cancer.fr/catalogue-des-publications/recherche-de-deficit-en-dihydropyrimidine-deshydrogenase-en-vue-de-prevenir-certaines-toxicites-severes-survenant-sous-traitement-comportant-des-fl
2023
false
false
false
France
mass screening
Capecitabine
fluorouracil
uracil
poisoning
health technology assessment
dihydropyrimidine dehydrogenase deficiency

---
https://ansm.sante.fr/actualites/traitement-par-fluoropyrimidines-5-fluorouracile-et-capecitabine-et-deficit-en-dihydropyrimidine-deshydrogenase-dpd-lansm-invite-les-professionnels-de-sante-a-appliquer-les-nouvelles-recommandations-emises-par-linca-et-la-has
2018
false
false
false
false
France
French
guidelines for drug use
Capecitabine
fluorouracil
uracil
mass screening
dihydropyrimidine dehydrogenase deficiency
antimetabolites, antineoplastic
blood chemical analysis
Drug-Related side effects and adverse reactions

---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds

---
https://www.has-sante.fr/portail/jcms/c_2775799/fr/viekirax-exviera
2017
false
false
false
false
France
French
evaluation of the transparency committee
drug combinations
administration, oral
hepatitis C, chronic
drug therapy, combination
adult
anilides
carbamates
antiviral agents
macrocyclic compounds
ritonavir
sulfonamides
uracil
treatment outcome
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
ombitasvir
dasabuvir
paritaprevir
dasabuvir
ombitasvir, paritaprevir and ritonavir
ombitasvir
dasabuvir
paritaprevir

---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles

---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil

---
Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/61274a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
hepatitis C, chronic
adult
direct acting antivirals
antiviral agents
Hepatitis B reactivation
hepatitis B
risk assessment
product surveillance, postmarketing
canada
patient education handout
risk
daclatasvir
Sofosbuvir
Simeprevir
velpatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
dasabuvir
ritonavir
sofosbuvir-velpatasvir drug combination
daclatasvir
dasabuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
sulfonamides
uracil
uracil
drug combinations

---
Summary Safety Review - Incretin-Based Therapies - Assessing the Potential Risk of Pancreatic Cancer
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/incretin-fra.php
2016
false
false
false
Canada
French
English
diabetes mellitus, type 2
pharmacovigilance note
incretins
pancreatic neoplasms
risk
saxagliptin
alogliptin
hypoglycemic agents
Sitagliptin Phosphate
Liraglutide
drug evaluation
risk assessment
canada
peptides
venoms
adamantane
adamantane
dipeptides
piperidines
uracil
uracil
Exenatide

---
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-05-fra.php#mise_%C3%A0_jour
2016
false
false
false
Canada
French
pharmacovigilance note
socioeconomic factors
monograph
cirrhosis of liver, nos
patients
has patient
sectional
indicators
decompensation
administration of medication, nos
effective
drug interactions
disease of liver, nos
observation
drug monitoring
pharmacovigilance
dasabuvir
contraindication to
liver cirrhosis
risk
effect modifier, epidemiologic
drug interaction
hepatic failure, nos
positive
administration
hepatic insufficiency
medication adherence
cirrhosis
monograph
indicators and reagents
observation
drug monitoring
dasabuvir
organization and administration
fibrosis
sulfonamides
uracil

---
Information Update - Risk of Serious Liver Injury associated with Hepatitis C Treatments: Holkira Pak and Technivie
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55800a-fra.php
2015
false
false
false
Canada
French
English
Chemical and Drug Induced Liver Injury
pharmacovigilance note
antiviral agents
hepatitis C, chronic
drug combinations
antiviral agents
ombitasvir
paritaprevir
ritonavir
dasabuvir
ombitasvir
dasabuvir
anilides
carbamates
sulfonamides
uracil
uracil
macrocyclic compounds
Contraindications, Drug

---
http://www.has-sante.fr/portail/jcms/c_2025737/fr/exviera/viekirax
http://www.has-sante.fr/portail/jcms/c_2025737/fr/viekirax-ombitasvir/paritaprevir/ritonavir-association-fixe-dantiviraux-a-action-directe-exviera-dasabuvir-antiviral-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
drug combinations
administration, oral
hepatitis C, chronic
drug therapy, combination
adult
anilides
anilides
carbamates
carbamates
antiviral agents
antiviral agents
macrocyclic compounds
macrocyclic compounds
ritonavir
ritonavir
sulfonamides
sulfonamides
uracil
treatment outcome
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 4 (organism)
ombitasvir
paritaprevir
dasabuvir
paritaprevir
dasabuvir
ombitasvir, paritaprevir and ritonavir
ombitasvir
dasabuvir

---
https://www.ema.europa.eu/medicines/human/EPAR/Exviera
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
sulfonamides
sulfonamides
antiviral agents
antiviral agents
drug approval
europe
uracil
adult
hepatitis C, chronic
drug therapy, combination
administration, oral
enzyme inhibitors
enzyme inhibitors
NS-5b protein, hepatitis C virus
NS-5 protein, hepatitis C virus
drug monitoring
product surveillance, postmarketing
risk management
drug interactions
pregnancy
breast feeding
drug resistance, viral
clinical trials as topic
drug evaluation, preclinical
dasabuvir
dasabuvir
dasabuvir
viral nonstructural proteins
dasabuvir
dasabuvir

---
http://www.has-sante.fr/portail/jcms/c_1774095/fr/vipidia
2014
false
false
false
France
French
evaluation of the transparency committee
alogliptin
Alogliptin Benzoate
administration, oral
insurance, health, reimbursement
alogliptin
hypoglycemic agents
incretins
dipeptidyl-peptidase iv inhibitors
drug therapy, combination
diabetes mellitus, type 2
adult
treatment outcome
Product containing alogliptin (medicinal product)
Product containing precisely alogliptin benzoate 6.25 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 12.5 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 25 milligram/1 each conventional release oral tablet (clinical drug)
piperidines
uracil
uracil

---
http://www.has-sante.fr/portail/jcms/c_1774100/fr/vipdomet
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
drug combinations
metformin
hypoglycemic agents
Alogliptin Benzoate
metformin and alogliptin
alogliptin
dipeptidyl-peptidase iv inhibitors
incretins
adult
diabetes mellitus, type 2
treatment outcome
insurance, health, reimbursement
drug therapy, combination
piperidines
uracil
uracil

---
http://www.has-sante.fr/portail/jcms/c_1244174/uft
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-05/uft_11042012_avis_ct10161.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_400954
http://www.has-sante.fr/portail/display.jsp?id=c_399171
2012
France
French
evaluation of the transparency committee
tegafur, combinations
drug combinations
administration, oral
insurance, health, reimbursement
UFT(R) drug
tegafur
uracil
antineoplastic agents
neoplasm metastasis
colorectal neoplasms
antineoplastic combined chemotherapy protocols
leucovorin

---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=101092
2011
France
scientific and technical information
hyper-IgM immunodeficiency syndrome
uracil

---
http://www.has-sante.fr/portail/display.jsp?id=c_601786
http://www.has-sante.fr/portail/display.jsp?id=c_601796
2007
France
French
Contraindications, Procedure
uracil
drug combinations
colorectal neoplasms
neoplasm metastasis
drug therapy, combination
capsules
administration, oral
antimetabolites, antineoplastic
drug prescriptions
uracil
tegafur
antimetabolites, antineoplastic
uracil
tegafur
antimetabolites, antineoplastic
pregnancy
drug interactions
uracil
tegafur
antimetabolites, antineoplastic
leucovorin
tegafur
continuity of patient care
adult
tegafur, combinations
UFT(R) drug
guidelines for drug use
Contraindications, Drug

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.